Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

I would argue that the "dynamic complexities" of CNS diseases should cause investors to be highly skeptical of the simplistic notion that "restoring cellular homeostasis" by A273 will cure CNS diseases, cancer, pain, high cholesterol, insomnia, high blood pressure, etc. Here's why.

In a nutshell, an article in yesterday's New York Times Magazine, titled The Search for Cancer Treatment Beyond Mutant-Hunting; Can we expand our ideas of what personalized medicine could mean?, pointed out the mere identification of a patients' aberrant genes is insufficient to develop an effective personalized medicine approach because of the great complexity of the body, how it gets sick and how it maintains health. By the way, this was an important topic of discussion at the recent American Society of Clinical Oncology annual meeting.

While the Times' article is focused on cancer, CNS diseases are at least as complex in terms of the myriad of genetic aberrations and interactions involved as well as the dynamic complexities of the human body that represent the still poorly understood bigger picture of how people stay well, get sick or get well.